A changing treatment landscape for multiple sclerosis: challenges and opportunities

被引：47
作者：
Piehl, F. [1 ]
机构：
[1] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden
来源：
JOURNAL OF INTERNAL MEDICINE | 2014年 / 275卷 / 04期
关键词：
multiple sclerosis; immunomodulatory therapy; biological therapies; randomized controlled trial; PLACEBO-CONTROLLED TRIAL; FUMARIC-ACID ESTERS; MEMORY T-CELLS; DOUBLE-BLIND; NATALIZUMAB TREATMENT; CONTROLLED PHASE-3; INTERFERON-BETA; DISEASE-ACTIVITY; BREAKTHROUGH DISEASE; GLATIRAMER ACETATE;
D O I：
10.1111/joim.12204
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Multiple sclerosis (MS) is primarily an autoimmune disease of the central nervous system, but also encompasses prominent neurodegenerative aspects. A significant proportion of MS patients will develop neurological disability over time and up until recently treatment options have been limited. However, MS treatment is now at a stage of rapid progress, with several new drugs that have reached the market or will be launched in the near future. This provides new opportunities for individualized treatment, but also creates new challenges regarding monitoring of disease activity, long-term safety issues and efficacy, not least in patients with progressive disease.
引用
收藏
页码：364 / 381
页数：18
相关论文
共 89 条
  • [11] Alemtuzumab more effective than interferon β-1a at 5-year follow-up of CAMMS223 Clinical Trial
    Coles, A. J.
    Fox, E.
    Vladic, A.
    Gazda, S. K.
    Brinar, V.
    Selmaj, K. W.
    Skoromets, A.
    Stolyarov, I.
    Bass, A.
    Sullivan, H.
    Margolin, D. H.
    Lake, S. L.
    Moran, S.
    Palmer, J.
    Smith, M. S.
    Compston, D. A. S.
    [J]. NEUROLOGY, 2012, 78 (14) : 1069 - 1078
  • [12] Coles AJ, 1999, ANN NEUROL, V46, P296, DOI 10.1002/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO
  • [13] 2-#
  • [14] Coles AJ, 2008, NEW ENGL J MED, V359, P1786, DOI 10.1056/NEJMoa0802670
  • [15] Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial
    Coles, Alasdair J.
    Twyman, Cary L.
    Arnold, Douglas L.
    Cohen, Jeffrey A.
    Confavreux, Christian
    Fox, Edward J.
    Hartung, Hans-Peter
    Havrdova, Eva
    Selmaj, Krzysztof W.
    Weiner, Howard L.
    Miller, Tamara
    Fisher, Elizabeth
    Sandbrink, Rupert
    Lake, Stephen L.
    Margolin, David H.
    Oyuela, Pedro
    Panzara, Michael A.
    Compston, D. Alastair S.
    [J]. LANCET, 2012, 380 (9856) : 1829 - 1839
  • [16] Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study
    Comi, G.
    Pulizzi, A.
    Rovaris, M.
    Abramsky, O.
    Arbizu, T.
    Boiko, A.
    Gold, R.
    Havrdova, E.
    Komoly, S.
    Selmaj, K. W.
    Sharrack, B.
    Filippi, M.
    [J]. LANCET, 2008, 371 (9630) : 2085 - 2092
  • [17] Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis
    Comi, Giancarlo
    Jeffery, Douglas
    Kappos, Ludwig
    Montalban, Xavier
    Boyko, Alexey
    Rocca, Maria A.
    Filippi, Massimo
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (11) : 1000 - 1009
  • [18] Multiple sclerosis
    Compston, Alastair
    Coles, Alasdair
    [J]. LANCET, 2008, 372 (9648) : 1502 - 1517
  • [19] Natural history of multiple sclerosis: a unifying concept
    Confavreux, C
    Vukusic, S
    [J]. BRAIN, 2006, 129 : 606 - 616
  • [20] Relapse and disability outcomes in patients with multiple sclerosis treated with fingolimod: subgroup analyses of the double-blind, randomised, placebo-controlled FREEDOMS study
    Devonshire, Virginia
    Havrdova, Eva
    Radue, Ernst Wilhelm
    O'Connor, Paul
    Zhang-Auberson, Lixin
    Agoropoulou, Catherine
    Haering, Dieter Adrian
    Francis, Gordon
    Kappos, Ludwig
    [J]. LANCET NEUROLOGY, 2012, 11 (05) : 420 - 428
123456789